
PIPRA AG is a Swiss-based company providing an AI-driven clinical decision support software designed to prevent delirium in hospitals. Their CE-marked Class IIa medical device automatically identifies patients at risk of delirium using routine clinical data, enabling targeted prevention and reducing delirium incidence by up to 30%. The solution integrates with hospital EHR systems to deliver automated alerts, daily reports, and dashboards, significantly reducing manual risk assessment workload by 95% and lowering costs by approximately 2.5 million CHF per 1000 patients. PIPRA offers a 12-week implementation program for smooth integration and ongoing support. Their product is validated through multiple peer-reviewed studies and clinical trials, positioning them as a leader in delirium risk prediction and management in healthcare settings.

PIPRA AG is a Swiss-based company providing an AI-driven clinical decision support software designed to prevent delirium in hospitals. Their CE-marked Class IIa medical device automatically identifies patients at risk of delirium using routine clinical data, enabling targeted prevention and reducing delirium incidence by up to 30%. The solution integrates with hospital EHR systems to deliver automated alerts, daily reports, and dashboards, significantly reducing manual risk assessment workload by 95% and lowering costs by approximately 2.5 million CHF per 1000 patients. PIPRA offers a 12-week implementation program for smooth integration and ongoing support. Their product is validated through multiple peer-reviewed studies and clinical trials, positioning them as a leader in delirium risk prediction and management in healthcare settings.
Product: CE‑marked AI clinical decision support software to predict and prevent delirium
Impact: Reported reduction in delirium incidence and nursing workload in validated studies
HQ & Founded: Zürich, Switzerland; founded 2019
Team size: Approximately 18 employees
Recent funding: Seed round reported on 2023-01-23
Delirium risk prediction and prevention in hospital/clinical settings (postoperative and inpatient care).
2019
Digital Health / MedTech
Reported as most recent round
“Newchip Accelerator; Zürcher Kantonal Bank reported among investors”